Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

Hepatic adenoma is an uncommon, benign liver tumor. Benign means that it’s not cancerous. It’s also known as hepatocellular adenoma or liver cell adenoma. Hepatic adenoma is extremely rare. It most ...

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.

Hepatic hydrothorax is a respiratory condition that affects people with cirrhosis and other serious liver issues. It occurs when fluid builds up in the pleural space. Hepatic hydrothorax is a ...

THE liver acts as a selective barrier between the gastrointestinal tract and the systemic circulation, metabolizing, detoxifying and elaborating for further physiologic disposition various substances ...

You've had liver disease for a while, but now you notice something different about the way you act and feel. Maybe you forget things or get confused when someone's talking to you. Your friends may ...

Congenital hepatic fibrosis is a type of liver disease that is present from birth. It typically affects the function of the bile ducts and the veins that carry blood from the digestive tract to the ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...